PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy

PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy

Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors. Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma. Her...

Full description

Bibliographic Details
Main Authors: Dan Lu, Zepeng Xu, Ding Zhang, Min Jiang, Kefang Liu, Juanhua He, Dongli Ma, Xiaopeng Ma, Shuguang Tan, George F. Gao, Yan Chai
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Immunology
Subjects:
PD-1
antibody
N58 glycosylation
cemiplimab
immune checkpoint therapy (ICT)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.826045/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.826045/full

Similar Items